Mayo Clinic and Mayo Medical Laboratories Collaborate with bioTheranostics

Mayo Clinic and Mayo Medical Laboratories have signed a collaboration agreement with bioTheranostics, a leading provider of molecular diagnostics solutions for cancer. Through the agreement, Mayo Clinic and Mayo Medical Laboratories will offer bioTheranostics’ molecular cancer classification test, as part of its surgical pathology consultations, to aid in the management of patients with metastatic cancer.

The CancerTYPE ID test will be available to Mayo Clinic physicians and patients at its campuses in the Midwest, Arizona and Florida, as well as to more than 5,000 hospitals around the world served by Mayo Medical Laboratories.

CancerTYPE ID, an industry-leading molecular cancer classifier, predicts tumor type in patients with metastatic cancers, which affect more than 400,000 patients in the United States each year and are among the most difficult to diagnose and treat. The CancerTYPE ID test is supported by significant clinical evidence confirming its diagnostic accuracy, clinical utility in tumor classification and impact on patient outcomes.

Kelley Luedke

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.